From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history

RituxME is a clinical trial of the rituximab ME/CFS research group at the Dept. of Oncology and Medical Physics at Haukeland University Hospital, Bergen, Norway. Senior Consultant Øystein Fluge and Professor Olav Mella are the study supervisors.[1] The final study, published in 2019, showed no overall improvement.[2]

Notable studies[edit | edit source]

Evidence[edit | edit source]

A substudy showing improvement in post-occlusive reactive hyperemia (PORH) but not Flow-Mediated Dilation (FMD) after 18 months rituximab, no changes in symptoms
  • 2019, B-Lymphocyte Depletion in Patients With Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial[2] - (Full text)
  • 2016, Serum BAFF and APRIL Levels, T-Lymphocyte Subsets, and Immunoglobulins after B-Cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Myalgic Encephalopathy/Chronic Fatigue Syndrome.[4] - (Full text)
  • 2015, B-Lymphocyte Depletion in Myalgic Encephalopathy/ Chronic Fatigue Syndrome. An Open-Label Phase II Study with Rituximab Maintenance Treatment[5] - (Full text)

See also[edit | edit source]

Learn more[edit | edit source]

References[edit | edit source]